

Boris Ferko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/162756/publications.pdf>

Version: 2024-02-01

31
papers

1,695
citations

236925

25
h-index

434195

31
g-index

31
all docs

31
docs citations

31
times ranked

1940
citing authors

#	ARTICLE	IF	CITATIONS
1	Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. PLoS ONE, 2015, 10, e0138722.	2.5	11
2	Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virology Journal, 2014, 11, 69.	3.4	34
3	Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. International Journal of Molecular Sciences, 2012, 13, 5674-5699.	4.1	22
4	Sublingual Immunization with a Live Attenuated Influenza A Virus Lacking the Nonstructural Protein 1 Induces Broad Protective Immunity in Mice. PLoS ONE, 2012, 7, e39921.	2.5	31
5	Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. Vaccine, 2011, 29, 3517-3524.	3.8	36
6	Single HA2 Mutation Increases the Infectivity and Immunogenicity of a Live Attenuated H5N1 Intranasal Influenza Vaccine Candidate Lacking NS1. PLoS ONE, 2011, 6, e18577.	2.5	75
7	Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Biotechnology Journal, 2010, 5, 17-23.	3.5	35
8	Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis. Journal of Virological Methods, 2010, 167, 17-22.	2.1	24
9	A Novel Type of Influenza Vaccine: Safety and Immunogenicity of Replication-Deficient Influenza Virus Created by Deletion of the Interferon Antagonist NS1. Journal of Infectious Diseases, 2010, 201, 354-362.	4.0	118
10	Preclinical Evaluation of a Replication-Deficient Intranasal Δ NS1 H5N1 Influenza Vaccine. PLoS ONE, 2009, 4, e5984.	2.5	66
11	Expression, Purification, and In Vivo Administration of a Promising Anti-Idiotypic HIV-1 Vaccine. Molecular Biotechnology, 2008, 39, 119-125.	2.4	6
12	Azidothymidine inhibits melanoma cell growth in vitro and in vivo. Melanoma Research, 2008, 18, 314-321.	1.2	27
13	GMP Production of Liposomes—A New Industrial Approach. Journal of Liposome Research, 2006, 16, 311-319.	3.3	85
14	Influenza Virus NS Vectors Expressing the Mycobacterium tuberculosis ESAT-6 Protein Induce CD4 + Th1 Immune Response and Protect Animals against Tuberculosis Challenge. Vaccine Journal, 2006, 13, 898-904.	3.1	54
15	Immunoglobulin G specifically binding plant N-glycans with high affinity could be generated in rabbits but not in mice. Glycobiology, 2006, 16, 349-357.	2.5	52
16	Virus-Coated Layer-by-Layer Colloids as a Multiplex Suspension Array for the Detection and Quantification of Virus-Specific Antibodies. Clinical Chemistry, 2006, 52, 1575-1583.	3.2	31
17	Live Attenuated Influenza Virus Expressing Human Interleukin-2 Reveals Increased Immunogenic Potential in Young and Aged Hosts. Journal of Virology, 2006, 80, 11621-11627.	3.4	33
18	Establishment of a strategy for the rapid generation of a monoclonal antibody against the human protein SNEV (hNMP200) by flow-cytometric cell sorting. Journal of Immunological Methods, 2005, 307, 13-23.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1 β and 18. <i>Journal of General Virology</i> , 2005, 86, 185-195.	2.9	161
20	Trimeric Membrane-anchored gp41 Inhibits HIV Membrane Fusion. <i>Journal of Biological Chemistry</i> , 2005, 280, 4095-4101.	3.4	40
21	Generation of an Influenza A Virus Vector Expressing Biologically Active Human Interleukin-2 from the NS Gene Segment. <i>Journal of Virology</i> , 2005, 79, 10672-10677.	3.4	48
22	Immunogenicity and Protection Efficacy of Replication-Deficient Influenza A Viruses with Altered NS1 Genes. <i>Journal of Virology</i> , 2004, 78, 13037-13045.	3.4	109
23	Rescue of influenza virus expressing GFP from the NS1 reading frame. <i>Virology</i> , 2004, 324, 67-73.	2.4	85
24	Live cold-adapted influenza A vaccine produced in Vero cell line. <i>Virus Research</i> , 2004, 103, 187-193.	2.2	29
25	Distinct host range of influenza h3n2 virus isolates in vero and mdck cells is determined by cell specific glycosylation pattern. <i>Virology</i> , 2003, 307, 90-97.	2.4	55
26	Reepithelialization of experimental scalds effected by topically applied superoxide dismutase: controlled animal studies. <i>Wound Repair and Regeneration</i> , 2002, 10, 366-371.	3.0	37
27	Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. <i>Aids</i> , 2002, 16, 667-668.	2.2	24
28	Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. <i>European Journal of Pharmaceutical Sciences</i> , 2001, 14, 63-67.	4.0	62
29	Hyperattenuated Recombinant Influenza A Virus Nonstructural-Protein-Encoding Vectors Induce Human Immunodeficiency Virus Type 1 Nef-Specific Systemic and Mucosal Immune Responses in Mice. <i>Journal of Virology</i> , 2001, 75, 8899-8908.	3.4	66
30	Chimeric Influenza Virus Replicating Predominantly in the Murine Upper Respiratory Tract Induces Local Immune Responses against Human Immunodeficiency Virus Type 1 in the Genital Tract. <i>Journal of Infectious Diseases</i> , 1998, 178, 1359-1368.	4.0	46
31	Transfectant Influenza A Viruses with Long Deletions in the NS1 Protein Grow Efficiently in Vero Cells. <i>Journal of Virology</i> , 1998, 72, 6437-6441.	3.4	186